Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-06-12Clinical Trial Update: HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
A clinical trial update reports the termination of the Phase 1/2 study evaluating HB-302/HB-301 therapy in metastatic castration-resistant p…
-
CLINICAL_TRIALS research · 2024-06-11Clinical Trial Update: Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) [Phase 2]
A Phase 2 clinical trial evaluating pembrolizumab in combination with carboplatin and cabazitaxel for aggressive metastatic castration-resis…
-
CLINICAL_TRIALS trial_result · 2024-06-10Clinical Trial Update: Cisplatin in Castration Resistant Prostate Cancer [EARLY_Phase 1]
An early-phase trial update reports on the use of cisplatin for castration-resistant prostate cancer, noting the study status is completed.
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer [EARLY_Phase 1]
This document reports an early-phase trial evaluating T-cell responses to neoantigens after treatment with ipilimumab in men with metastatic…
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies [Phase 1]
This Phase 1 trial evaluated the safety and tolerability of immunotherapy combinations across multiple advanced cancers and has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-05-23Clinical Trial Update: Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer [Phase 2]
Phase 2 trial of Disitamab Vedotin for HER2-expressing locally advanced or metastatic castration-resistant prostate cancer is currently recr…
-
CLINICAL_TRIALS trial_result · 2024-05-17Clinical Trial Update: Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 2]
Phase 2 study of SRF617 in combination with AB928 (etrumadenant) and AB122 (zimberelimab) for metastatic castration-resistant prostate cance…
-
CLINICAL_TRIALS trial_result · 2024-05-14Clinical Trial Update: Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) [Phase 1]
Exelixis reports that the QUARTZ-101 Phase 1 trial of XL102 as a single agent and in combination therapy for solid tumors has been terminate…
-
CLINICAL_TRIALS research · 2024-05-08Clinical Trial Update: MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer [NA]
Update on the MENCORE-2 trial evaluating audio recordings to support decision-making in advanced/metastatic prostate cancer.
-
CLINICAL_TRIALS trial_result · 2024-05-07Clinical Trial Update: CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib [Phase 3]
Phase 3 rollover study CATCH-R provides continued access to rucaparib for eligible patients with metastatic castration-resistant prostate ca…
-
CLINICAL_TRIALS withdrawal · 2024-05-02Clinical Trial Update: Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations [Phase 1]
A Phase 1 trial evaluating the addition of magrolimab to olaparib for BRCA-mutated metastatic breast cancer or castration-resistant prostate…
-
CLINICAL_TRIALS trial_result · 2024-04-29Clinical Trial Update: [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2 [Phase 2]
A Phase 2 clinical trial update for Lu-177 Ludotadipep in metastatic castration-resistant prostate cancer, with the study status listed as a…
-
CLINICAL_TRIALS research · 2024-04-29Clinical Trial Update: [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application [Phase 1, Phase 2]
This entry reports a Phase 1/2 clinical trial of Lu-177 Ludotadipep for metastatic castration-resistant prostate cancer, with ongoing recrui…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: Abiraterone Acetate in Combination With Tildrakizumab [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating abiraterone acetate in combination with tildrakizumab for metastatic castration-resistant prostate can…
-
CLINICAL_TRIALS trial_result · 2024-04-17Clinical Trial Update: ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer [Phase 2]
Phase 2 trial comparing ModraDoc006/r to Docetaxel IV in metastatic castration-resistant prostate cancer has completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2024-04-16Clinical Trial Update: Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones [Phase 2]
NCI-sponsored Phase 2 trial evaluating Sn-117m-DTPA bone-targeted radiation for cancer-related bone pain in men with prostate cancer that ha…
-
CLINICAL_TRIALS trial_result · 2024-04-15Clinical Trial Update: Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide [Phase 2]
Phase 2 clinical trial investigating biomarker analysis in castration-resistant prostate cancer patients treated with docetaxel followed by …
-
CLINICAL_TRIALS trial_result · 2024-04-12Clinical Trial Update: Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations [Phase 1]
Phase 1 platform study exploring translational endpoints to inform use of novel combinations in metastatic castration-resistant prostate can…
-
CLINICAL_TRIALS trial_result · 2024-04-05Clinical Trial Update: A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts [Phase 2]
Phase 2 clinical trial update evaluating safety, pharmacokinetics, and clinical effects of IV PT-112 in advanced solid tumors with dose expa…
-
CLINICAL_TRIALS trial_result · 2024-03-01Clinical Trial Update: A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma [Phase 2]
This Phase 2 trial evaluating NIR178 in combination with PDR001 across multiple solid tumors and non-Hodgkin lymphoma was terminated, with r…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage [Phase 2, Phase 3]
A clinical trial evaluating docetaxel alone or with enzalutamide for metastatic castration-resistant prostate cancer previously treated with…
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 1, Phase 2]
Phase 1/2 trial of ADXS31-142 alone and with pembrolizumab in previously treated metastatic castration-resistant prostate cancer completed; …
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) [Phase 2]
Phase 2 clinical trial update examining radiation plus adebrelimab in metastatic castration-resistant prostate cancer with imaging-measurabl…
-
CLINICAL_TRIALS trial_result · 2024-02-07Clinical Trial Update: Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer [Phase 2]
Phase 2 trial investigating enzalutamide with Lu-PSMA-617 versus enzalutamide alone for metastatic castration-resistant prostate cancer.
-
CLINICAL_TRIALS trial_result · 2024-02-05Clinical Trial Update: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent [Phase 3]
Phase 3 trial evaluating VERU-111 for metastatic castration-resistant prostate cancer after AR-targeting therapy has been terminated.